Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05600036 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis | PHASE2 | COMPLETED | 228 | — | — | Sep 27, 2022 | Jul 25, 2023 | Jun 18, 2025 | 53 | United States, Canada +1 |
Proportion of patients with moderate to severe psoriasis achieving ≥75% reduction in PASI score
| Arm | Type | Description |
|---|---|---|
| ESK-001 Dose Level 1 | EXPERIMENTAL | ESK-001 administered as an oral tablet |
| ESK-001 Dose Level 2 | EXPERIMENTAL | ESK-001 administered as an oral tablet |
| ESK-001 Dose Level 3 | EXPERIMENTAL | ESK-001 administered as an oral tablet |
| ESK-001 Dose Level 4 | EXPERIMENTAL | ESK-001 administered as an oral tablet |
| ESK-001 Dose Level 5 | EXPERIMENTAL | ESK-001 administered as an oral tablet |
| Placebo | PLACEBO_COMPARATOR | Placebo administered as an oral tablet |
| Name | Type | Description |
|---|---|---|
| ESK-001 | DRUG | Oral tablet |
| Placebo | DRUG | Oral tablet |
Inclusion Criteria: * Total body weight \>40 kg (88 lb) * Men and woman age 18-75 * Men and Women must use highly effective methods of contraception for the entirety of the study Exclusion Criteria: * History of malignancy within the last 5 years * Positive for HIV, Hepatitis B or C * History of ...